Skip to search formSkip to main contentSkip to account menu

NVP-LAF237

Known as: NVP-LAF-237 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2018
Highly Cited
2018
Abstract Background Imatinib and second-generation tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib have statistically… 
Review
2015
Review
2015
As a result of our efforts to discover novel p53:MDM2 protein-protein interaction inhibitors useful for treating cancer, the… 
2015
2015
NVP‐AUY922 (AUY; Luminespib) with or without bortezomib showed preclinical activity against multiple myeloma (MM) cells. This… 
Highly Cited
2010
Highly Cited
2010
Angiogenesis is a critical step in tumor development, in which vascular endothelial growth factor (VEGF) is a key growth aspect… 
Highly Cited
2010
Highly Cited
2010
Background:Heat-shock protein 90 (Hsp90) has a crucial role in both the stabilisation and regulation of various proteins… 
2009
2009
Shifting substrate oxidation in heart muscle from fatty acids to glucose (substrate-switch) may improve contractile function in… 
2008
2008
An attractive target for therapeutic intervention is constitutively activated, mutant FLT3, which is expressed in a subpopulation… 
Highly Cited
2003
Highly Cited
2003
Dipeptidyl peptidase IV (DPP-IV) inhibition has the potential to become a valuable therapy for type 2 diabetes. The synthesis and… 
Highly Cited
2002
Highly Cited
2002
OBJECTIVE Glucagon-like peptide-1 (GLP-1) has been proposed as a new treatment modality for type 2 diabetes. To circumvent the… 
Highly Cited
2002
Highly Cited
2002
OBJECTIVES Inhibitors of the glucagon-like peptide-1 (GLP-1)-degrading enzyme, dipeptidyl peptidase IV (DPPIV), are being…